Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Tuberculosis and HIV news

Show

From To
TB Treatment May Leave Some Patients Contagious

The World Health Organization’s dosage guidelines for two leading tuberculosis medications may be far too low for patients with H.I.V., allowing them to remain contagious for longer than necessary, a new study has found.

Published
09 April 2018
From
New York Times
Study finds more than 80 percent of patients needing WHO recommended last resort treatment for drug-resistant TB not getting it

Roughly four years after the World Health Organization recommended that the newest drugs against tuberculosis be made available to patients for whom they represented a last resort, fewer than a fifth of patients needing them have received them, according to a report in the International Journal of Tuberculosis and Lung Disease.

Published
06 April 2018
From
Science Speaks
UNAIDS calls for bold action to end TB and AIDS

Ahead of World TB Day 2018, UNAIDS is calling on all partners to take unprecedented and bold action to advance efforts to end tuberculosis (TB) and AIDS by 2030.

Published
23 March 2018
From
UNAIDS
WHO issues recommendations on management of isoniazid-resistant tuberculosis

Within the context of an ongoing extensive review of evidence on treatment of drug-resistant (TB) taking place in 2018, the World Health Organization (WHO) has issued a Supplement to its current drug-resistant TB treatment guidelines, providing recommendations for the management of isoniazid-resistant TB. These will be incorporated into the Consolidated Guidelines for Treatment and Care of Drug-resistant TB envisaged by WHO later in 2018.

Published
22 March 2018
From
World Health Organization
J&J, Macleods in talks for licence deal of tuberculosis drug

Mumbai-based Macleods Pharmaceuticals and US drug giant Johnson & Johnson(J&J) are in talks for a voluntary licence deal for the tuberculosis drug Bedaquiline, EThas learnt.

Published
13 March 2018
From
Economic Times
Higher rifampin doses safe for patients with pulmonary TB

Results of a phase 2 randomized clinical trial show that up to twice the standard daily dose of rifampin was safe in patients with pulmonary tuberculosis. The findings suggest that TB therapy can be shortened using higher doses, which could potentially improve outcomes without increasing toxicity.

Published
07 March 2018
From
Healio
Dolutegravir and Rifapentine study stopped due to serious toxicities

A study examining pharmacokinetic interactions between the first-line HIV drug dolutegravir and a once-weekly tuberculosis regimen was terminated early after NIH researchers found that the combined use of the treatments led to “unexpected and serious toxicities” in healthy participants.

Published
01 March 2018
From
Medical Brief
TB vaccine trial results offer potential for BCG Revaccination, hope for subunit vaccines

Aeras, a nonprofit organization dedicated to developing vaccines against tuberculosis (TB), today announced results from an innovative clinical trial that provides encouraging new evidence that TB vaccines could prevent sustained infections in high-risk adolescents. In a prevention-of-infection Phase 2 trial conducted in South Africa, revaccination with the Bacille Calmette-Guerin (BCG) vaccine significantly reduced sustained TB infections in adolescents. An experimental vaccine candidate, H4:IC31, also reduced sustained infections, although not at statistically significant levels.

Published
19 February 2018
From
Eurekalert Medicine & Health
How both sides in Ukraine's war are losing the HIV battle

Displacement, aid delivery issues, and different strategies are all feeding a raging epidemic.

Published
16 February 2018
From
IRINnews.org
Promising MSF Research Highlights Immense Benefits, Need for Expanded Use of DR-TB Drug Combination

New research published today in The Lancet Infectious Diseases journal by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) provides strong evidence that a combination of two new drugs for tuberculosis (TB)—the world’s leading infectious disease killer—could be used to treat drug-resistant (DR-TB) forms of the disease. These findings encourage the wider use of these medicines in combination for DR-TB patients worldwide.

Published
14 February 2018
From
MSF press release
← First12345...63Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.